Survival of COVID-19 Patients Who Received Antiviral and Antiviral Therapy Combined with Anti-inflammation Therapy in a National Referral Hospital, Indonesia

ABSTRACT

BACKGROUND: COVID-19 has infected and spread over the whole earth. For the time being, there is no cure for COVID-19. Although several medications have the potential to be utilized at various stages of the disease, no therapy has yet been demonstrated to be completely successful. AIM: This study aims to determine survival of COVID-19 patients who received antiviral and antiviral therapy combined with anti-inflammation therapy in a National Referral Hospital, Indonesia. METHODS: COVID-19 patients treated at Dr. M Djamil General Hospital in Padang, Indonesia were the subject of an analytic investigation using a retrospective cohort design. From January to June 2021, data were gathered from patient medical records. Independent sample T test and Chi-square test were used to analyze subject characteristics data. The median survival and survival rates were calculated using Kaplan–Meier survival analysis. It is also subjected to cox-regression analysis to answer the study hypothesis. RESULTS: The mean age of the subjects who received antiviral and anti-inflammatory medication was 60.95 12.11 years, while the average age of those who received antiviral therapy was 56.72 17.80 years, with the highest sex being male in both groups (59.3% and 50.6%). Antiviral and antiviral medication, as well as anti-inflammatory therapy, had no effect on the length of stay of COVID-19 patients (p >0.05). Antiviral and antiviral therapy, as well as anti-inflammatory therapy, play a role in the outcome of COVID-19 patients (p < 0.05), with patients receiving antiviral and anti-inflammatory therapy being a preventive factor in the final outcome of patients compared to patients receiving antiviral therapy HR = 0.69 (95% CI 0.48–0.99). CONCLUSION: When compared to patients who just got antiviral medication, the patients who received antiviral plus anti-inflammatory therapy had a better outcome. © 2022 Afriani Afriani, Sabrina Ermayanti, Irvan Medison, Russilawati Russilawati, Fenty Anggrainy, Yessy Susanty Sabri, Ricvan Dana Nindrea.